Corvus Pharmaceuticals Q4 net loss widens on higher R&D costs

Corvus Pharmaceuticals

12/03/2026 20:48

Overview

U.S. biopharma firm's Q4 net loss widened as operating expenses rose on clinical trial costs

Company reported positive Phase 1 safety and efficacy data for soquelitinib in atopic dermatitis

Corvus completed raising $189 mln in public offering, extending cash runway into Q2 2028

Outlook

Corvus expects cash to fund operations into the second qtr of 2028

Result Drivers

CLINICAL TRIAL COSTS - Higher research and development expenses were mainly due to increased clinical trial and manufacturing costs for soquelitinib, along with higher personnel costs

Research and development expenses for the three months and year ended December 31, 2025 totaled $9.9 million and $33.7 million, respectively, compared to $6.0 million and $19.4 million for the same periods in 2024.

Corvus had cash, cash equivalents and marketable securities of $56.8 million as compared to $52.0 million as of December 31, 2024

Company press release: ID:nGNX3P6Plt

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.15
Q4 Net Income
-$12.32 mln
Q4 Basic EPS
-$0.15
Q4 Operating Expenses
$12.22 mln
Q4 Operating Income
-$12.22 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $31.00, about 83.4% above its March 11 closing price of $16.90

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)